{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:39:02Z","timestamp":1791279542998,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00535-017-1415-1","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T21:42:47Z","timestamp":1513374167000},"page":"362-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":604,"title":["Current and future pharmacological therapies for NAFLD\/NASH"],"prefix":"10.1007","volume":"53","author":[{"given":"Yoshio","family":"Sumida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"key":"1415_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"issue":"47","key":"1415_CR2","first-page":"586","volume":"2012","author":"Y Eguchi","year":"2009","unstructured":"Eguchi Y, Hyogo H, Ono M, et al; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2009;2012(47):586\u201395.","journal-title":"J Gastroenterol"},{"key":"1415_CR3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152:1090\u20139.","journal-title":"Gastroenterology"},{"key":"1415_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdi.12645","volume":"8","author":"J Nakamura","year":"2017","unstructured":"Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001\u20132010: report of the committee on causes of death in diabetes mellitus. J Diabetes Invest. 2017;8:397\u2013410.","journal-title":"J Diabetes Invest"},{"key":"1415_CR5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al; American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592\u2013609.","journal-title":"Gastroenterology"},{"key":"1415_CR6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","volume":"50","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Hashimoto E, Ikejima K, Japanese Society of Gastroenterology, Japan Society of Hepatology. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364\u201377.","journal-title":"J Gastroenterol"},{"key":"1415_CR7","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"1415_CR8","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (In press).","DOI":"10.1002\/hep.29367"},{"key":"1415_CR9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"1415_CR10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/10715762.2013.837577","volume":"47","author":"Y Sumida","year":"2013","unstructured":"Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD\/NASH. Free Radic Res. 2013;47:869\u201380.","journal-title":"Free Radic Res."},{"key":"1415_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(02)00331-8","volume":"38","author":"Y Sumida","year":"2003","unstructured":"Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol. 2003;38:32\u20138.","journal-title":"J Hepatol"},{"key":"1415_CR12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","volume":"15","author":"T Hasegawa","year":"2001","unstructured":"Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001;15:1667\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.nut.2014.08.007","volume":"31","author":"M Yoneda","year":"2015","unstructured":"Yoneda M, Hasegawa T, Sato K. Vitamin E therapy for NAFLD\/NASH. Nutrition. 2015;31:898\u20139.","journal-title":"Nutrition."},{"key":"1415_CR14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"1415_CR15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","volume":"31","author":"K Sato","year":"2015","unstructured":"Sato K, Gosho M, Yamamoto T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923\u201330.","journal-title":"Nutrition."},{"key":"1415_CR16","first-page":"1445","volume":"60","author":"Y Sumida","year":"2013","unstructured":"Sumida Y, Naito Y, Tanaka S, et al. Long-term (\u2265\u00a02\u00a0year) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepatogastroenterology. 2013;60:1445\u201350.","journal-title":"Hepatogastroenterology"},{"key":"1415_CR17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","volume":"13","author":"ME Rinella","year":"2016","unstructured":"Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196\u2013205.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1415_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","volume":"142","author":"ER Miller 3rd","year":"2005","unstructured":"Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37\u201346.","journal-title":"Ann Intern Med"},{"key":"1415_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","volume":"301","author":"SM Lippman","year":"2009","unstructured":"Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39\u201351.","journal-title":"JAMA"},{"issue":"341","key":"1415_CR20","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","volume":"4","author":"M Sch\u00fcrks","year":"2010","unstructured":"Sch\u00fcrks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;4(341):c5702.","journal-title":"BMJ"},{"key":"1415_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","volume":"17","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96","journal-title":"BMC Gastroenterol."},{"key":"1415_CR22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/bbrc.1999.1403","volume":"263","author":"H Mitsuyoshi","year":"1999","unstructured":"Mitsuyoshi H, Nakashima T, Sumida Y, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263:537\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"1415_CR23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770\u20138.","journal-title":"Hepatology"},{"key":"1415_CR24","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297\u2013307.","journal-title":"N Engl J Med"},{"key":"1415_CR25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176\u201384.","journal-title":"Gastroenterology"},{"key":"1415_CR26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305\u201315.","journal-title":"Ann Intern Med"},{"key":"1415_CR27","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc13-2480","volume":"37","author":"AM DePaoli","year":"2014","unstructured":"DePaoli AM, Higgins LS, Henry RR, et al; INT131-007 Study Group. Can a selective PPAR\u03b3 modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014;37:1918\u201323.","journal-title":"Diabetes Care"},{"key":"1415_CR28","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(05)75907-9","volume":"353","author":"T Saibara","year":"1999","unstructured":"Saibara T, Onishi S, Ogawa Y, et al. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet. 1999;353:1802.","journal-title":"Lancet"},{"key":"1415_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ihj.2015.02.007","volume":"67","author":"SR Shetty","year":"2015","unstructured":"Shetty SR, Kumar S, Mathur RP, et al. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015;67:23\u20136.","journal-title":"Indian Heart J"},{"key":"1415_CR30","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","volume":"58","author":"B Staels","year":"2013","unstructured":"Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941\u201352.","journal-title":"Hepatology"},{"key":"1415_CR31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, et al; GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147\u201359.","journal-title":"Gastroenterology"},{"key":"1415_CR32","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","volume":"75","author":"N Ruzehaji","year":"2016","unstructured":"Ruzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75:2175\u201383.","journal-title":"Ann Rheum Dis"},{"key":"1415_CR33","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","volume":"76","author":"J Avouac","year":"2017","unstructured":"Avouac J, Konstantinova I, Guignabert C, et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017;76:1931\u201340","journal-title":"Ann Rheum Dis."},{"key":"1415_CR34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/hepr.12856","volume":"47","author":"Y Sumida","year":"2017","unstructured":"Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes. Hepatol Res. 2017;47:266\u201380","journal-title":"Hepatol Res."},{"key":"1415_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"1415_CR36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","volume":"45","author":"Y Eguchi","year":"2015","unstructured":"Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45:269\u201378.","journal-title":"Hepatol Res."},{"key":"1415_CR37","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1415_CR38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","volume":"5","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Athyros VG, Karagiannis A, et al. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017;5:329\u201330.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1415_CR39","doi-asserted-by":"crossref","unstructured":"Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol (In press).","DOI":"10.1007\/s00535-017-1364-8"},{"issue":"1","key":"1415_CR40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","volume":"42","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):25\u201332.","journal-title":"Diabetes Metab."},{"key":"1415_CR41","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","volume":"30","author":"Y Seino","year":"2014","unstructured":"Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245\u201355.","journal-title":"Curr Med Res Opin"},{"key":"1415_CR42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00535-012-0653-5","volume":"48","author":"T Shima","year":"2013","unstructured":"Shima T, Uto H, Ueki K, et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol. 2013;48:515\u201325.","journal-title":"J Gastroenterol"},{"key":"1415_CR43","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47:1072\u20138.","journal-title":"Hepatol Res."},{"key":"1415_CR44","doi-asserted-by":"crossref","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya C, Tsuchiya K, Shiba K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS ONE. 2016;11:e0151511.","journal-title":"PLoS ONE"},{"key":"1415_CR45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","volume":"64","author":"T Takase","year":"2017","unstructured":"Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64:363\u20137","journal-title":"Endocr J."},{"key":"1415_CR46","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","volume":"56","author":"A Takeda","year":"2017","unstructured":"Takeda A, Irahara A, Nakano A, et al. The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium\u2013glucose cotransporter 2 inhibitor ipragliflozin. Intern Med. 2017;56:2739\u201344","journal-title":"Intern Med."},{"key":"1415_CR47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","volume":"1","author":"N Akuta","year":"2017","unstructured":"Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium\u2013glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46\u201352.","journal-title":"Hepatol Commun."},{"key":"1415_CR48","doi-asserted-by":"crossref","unstructured":"Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab (In press).","DOI":"10.1111\/dom.13061"},{"key":"1415_CR49","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40:1364\u201372","journal-title":"Diabetes Care."},{"key":"1415_CR50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","volume":"40","author":"M Yoneda","year":"2010","unstructured":"Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res. 2010;40:566\u201373.","journal-title":"Hepatol Res."},{"key":"1415_CR51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","volume":"46","author":"H Park","year":"2011","unstructured":"Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101\u20137.","journal-title":"J Gastroenterol"},{"key":"1415_CR52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","volume":"61","author":"R Loomba","year":"2015","unstructured":"Loomba R, Sirlin CB, Ang B, et al; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239\u201350.","journal-title":"Hepatology"},{"key":"1415_CR53","doi-asserted-by":"crossref","unstructured":"Nakade Y, Murotani K, Inoue T, et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis. Hepatol Res (In press).","DOI":"10.1111\/hepr.12887"},{"key":"1415_CR54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","volume":"147","author":"AJ Sanyal","year":"2014","unstructured":"Sanyal AJ, Abdelmalek MF, Suzuki A, et al; EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377\u201384.","journal-title":"Gastroenterology"},{"key":"1415_CR55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","volume":"60","author":"E Scorletti","year":"2014","unstructured":"Scorletti E, Bhatia L, McCormick KG, et al; WELCOME Study. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211\u201321.","journal-title":"Hepatology"},{"key":"1415_CR56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323\u201332.","journal-title":"Gastroenterology"},{"key":"1415_CR57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, et al; K-877-04 Study Group. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343.","journal-title":"Atherosclerosis."},{"key":"1415_CR58","doi-asserted-by":"crossref","first-page":"42477","DOI":"10.1038\/srep42477","volume":"7","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477","journal-title":"Sci Rep."},{"key":"1415_CR59","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11745-001-0824-3","volume":"36","author":"T Gilat","year":"2001","unstructured":"Gilat T, Leikin-Frenkel A, Goldiner L, et al. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids. 2001;36:1135\u201340.","journal-title":"Lipids"},{"key":"1415_CR60","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","volume":"12","author":"R Safadi","year":"2014","unstructured":"Safadi R, Konikoff FM, Mahamid M, et al; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1415_CR61","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1172\/JCI63967","volume":"122","author":"DW Foster","year":"2012","unstructured":"Foster DW. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest. 2012;122:1958\u20139.","journal-title":"J Clin Invest."},{"key":"1415_CR62","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","volume":"40","author":"S Yokohama","year":"2004","unstructured":"Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222\u20135.","journal-title":"Hepatology"},{"key":"1415_CR63","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3748\/wjg.15.942","volume":"15","author":"EF Georgescu","year":"2009","unstructured":"Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15:942\u201354.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1415_CR64","doi-asserted-by":"crossref","first-page":"e0175717","DOI":"10.1371\/journal.pone.0175717","volume":"12","author":"S McPherson","year":"2017","unstructured":"McPherson S, Wilkinson N, Tiniakos D, et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE. 2017;12(4):e0175717.","journal-title":"PLoS ONE"},{"issue":"9972","key":"1415_CR65","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al; NASH Clinical Research Network. Farnesoid \u00d7 nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956\u201365.","journal-title":"Lancet"},{"key":"1415_CR66","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","volume":"288","author":"RH McMahan","year":"2013","unstructured":"McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288:11761\u201370.","journal-title":"J Biol Chem"},{"key":"1415_CR67","unstructured":"Vatner DF, Weismann D, Beddow SA, et al. Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab. 2013;305:E89\u2013100. Lipids. 2001;36:1135\u201340."},{"key":"1415_CR68","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","volume":"54","author":"CO Zein","year":"2011","unstructured":"Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610\u20139.","journal-title":"Hepatology"},{"key":"1415_CR69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","volume":"20","author":"J Du","year":"2014","unstructured":"Du J, Ma YY, Yu CH, et al. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014;20:569\u201377.","journal-title":"World J Gastroenterol"},{"key":"1415_CR70","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583\u201394.","journal-title":"J Hepatol"},{"key":"1415_CR71","doi-asserted-by":"crossref","unstructured":"Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology (In press).","DOI":"10.1002\/hep.29514"},{"key":"1415_CR72","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","volume":"35","author":"FJ Barreyro","year":"2015","unstructured":"Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of nonalcoholic steatohepatitis. Liver Int. 2015;35:953\u201366.","journal-title":"Liver Int"},{"key":"1415_CR73","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","volume":"125","author":"CJ Weston","year":"2015","unstructured":"Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125:501\u201320.","journal-title":"J Clin Invest."},{"key":"1415_CR74","first-page":"141","volume":"5","author":"M Mizrahi","year":"2012","unstructured":"Mizrahi M, Shabat Y, Ben Ya\u2019acov A, et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I\/II clinical trial in NASH. J Inflamm Res. 2012;5:141\u201350.","journal-title":"J Inflamm Res."},{"key":"1415_CR75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2007.04.019","volume":"47","author":"CA Rivera","year":"2007","unstructured":"Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571\u20139.","journal-title":"J Hepatol"},{"key":"1415_CR76","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373","journal-title":"J Hepatol."},{"key":"1415_CR77","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/dom.12309","volume":"16","author":"NA Prospero Di","year":"2014","unstructured":"Di Prospero NA, Artis E, Andrade-Gordon P, et al. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes Metab. 2014;16:1055\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1415_CR78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","volume":"147","author":"F Marra","year":"2014","unstructured":"Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147(3):577\u201394.","journal-title":"Gastroenterology"},{"key":"1415_CR79","doi-asserted-by":"crossref","unstructured":"Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology (In press).","DOI":"10.1002\/hep.29477"},{"key":"1415_CR80","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bioorg.2014.07.003","volume":"57","author":"HJ Moon","year":"2014","unstructured":"Moon HJ, Finney J, Ronnebaum T, et al. Human lysyl oxidase-like 2. Bioorg Chem. 2014;57:231\u201341.","journal-title":"Bioorg Chem"},{"key":"1415_CR81","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","volume":"230","author":"NC Henderson","year":"2009","unstructured":"Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160\u201371.","journal-title":"Immunol Rev"},{"key":"1415_CR82","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","volume":"44","author":"SA Harrison","year":"2016","unstructured":"Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 2016;44:1183.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR83","first-page":"30","volume":"4","author":"N Itoh","year":"2016","unstructured":"Itoh N, Nakayama Y, Konishi M. Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease. Front Cell Dev Biol. 2016;4:30.","journal-title":"Front Cell Dev Biol."},{"key":"1415_CR84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18:333\u201340.","journal-title":"Cell Metab"},{"issue":"Suppl1","key":"1415_CR85","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0168-8278(17)30582-2","volume":"66","author":"D Leeming","year":"2017","unstructured":"Leeming D, et al. Estimation of serum \u201ctrue collagen type III formation\u201d (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort. J Hepatol. 2017;66(Suppl1):S154.","journal-title":"J Hepatol"},{"key":"1415_CR86","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3082","volume":"19","author":"SM Reilly","year":"2013","unstructured":"Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-\u025b improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19:313\u201321.","journal-title":"Nat Med"},{"key":"1415_CR87","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","volume":"94","author":"U Costabel","year":"2017","unstructured":"Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017;94:408\u201315","journal-title":"Respiration."},{"key":"1415_CR88","doi-asserted-by":"crossref","first-page":"44754","DOI":"10.1038\/srep44754","volume":"7","author":"C Komiya","year":"2017","unstructured":"Komiya C, Tanaka M, Tsuchiya K, et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep. 2017;7:44754.","journal-title":"Sci Rep."},{"key":"1415_CR89","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","volume":"38","author":"JH Hoofnagle","year":"2013","unstructured":"Hoofnagle JH, Van Natta ML, Kleiner DE, et al; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR90","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1111\/hepr.12456","volume":"45","author":"Y Seko","year":"2015","unstructured":"Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015;45:E53\u201361.","journal-title":"Hepatol Res."},{"key":"1415_CR91","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.28484","volume":"63","author":"E Vilar-Gomez","year":"2016","unstructured":"Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63:1875\u201387.","journal-title":"Hepatology"},{"key":"1415_CR92","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","volume":"33","author":"E Hamaguchi","year":"2010","unstructured":"Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284\u20136.","journal-title":"Diabetes Care"},{"key":"1415_CR93","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, et al; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1415_CR94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Y Sumida","year":"2012","unstructured":"Sumida Y, Yoneda M, Hyogo H, et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.","journal-title":"BMC Gastroenterol."},{"key":"1415_CR95","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486\u2013501","journal-title":"Hepatology."},{"key":"1415_CR96","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dld.2007.10.019","volume":"40","author":"M Yoneda","year":"2008","unstructured":"Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40:371\u20138.","journal-title":"Dig Liver Dis."},{"key":"1415_CR97","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/hepr.12829","volume":"47","author":"K Seki","year":"2017","unstructured":"Seki K, Shima T, Oya H, et al. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res. 2017;47:882\u20139.","journal-title":"Hepatol Res."},{"key":"1415_CR98","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/hepr.12793","volume":"47","author":"A Okajima","year":"2017","unstructured":"Okajima A, Sumida Y, Taketani H, et al. Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. Hepatol Res. 2017;47:721\u201330.","journal-title":"Hepatol Res."},{"key":"1415_CR99","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626\u201337.","journal-title":"Gastroenterology"},{"key":"1415_CR100","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359\u201368.","journal-title":"Gut"},{"key":"1415_CR101","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","volume":"37","author":"D Roulot","year":"2017","unstructured":"Roulot D, Roudot-Thoraval F, NKontchou G, Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int. 2017;37:1897\u2013906","journal-title":"Liver Int."},{"key":"1415_CR102","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","volume":"63","author":"EM Koehler","year":"2016","unstructured":"Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63:138\u201347.","journal-title":"Hepatology"},{"key":"1415_CR103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/apt.13405","volume":"43","author":"I Doycheva","year":"2016","unstructured":"Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR104","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","volume":"49","author":"T Nakahara","year":"2014","unstructured":"Nakahara T, Hyogo H, Yoneda M, et al; Japan Study Group of Nonalcoholic Fatty Liver Disease. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477\u201384.","journal-title":"J Gastroenterol"},{"key":"1415_CR105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","volume":"49","author":"JP Ong","year":"2008","unstructured":"Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608\u201312.","journal-title":"J Hepatol"},{"key":"1415_CR106","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00535-009-0115-x","volume":"44","author":"N Oza","year":"2009","unstructured":"Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44:1203\u20138.","journal-title":"J Gastroenterol"},{"key":"1415_CR107","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577\u201386.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-017-1415-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,25]],"date-time":"2018-02-25T21:36:18Z","timestamp":1519594578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-017-1415-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s00535-017-1415-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732323132.793547490","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]}}}